Pharmacosmos A/S

Address: Roervangsvej 30

Sponsor Overview

assignment

Specializations

Haematology and Iron Overload

Pharmacosmos A/S supports clinical research in transfusion-dependent thalassemia, low-risk myelodysplastic syndromes, and related iron overload conditions, with interest in therapies that address chronic transfusion burden and iron accumulation.

α- and β-thalassemia
Myelodysplastic syndromes
Iron chelation

The sponsor’s research activity also extends to agents intended for iron removal and management of haemolysis in transfusion-related disorders.

Cardiology

Clinical trials include work in chronic heart failure with a focus on iron deficiency and its relationship to cardiovascular outcomes, including hospitalisation risk and cardiovascular mortality.

Symptomatic chronic heart failure
Intravenous iron therapy
Iron-deficient patients

This area reflects interest in correcting iron deficiency as part of supportive treatment in patients with persistent cardiac symptoms.

Oncology

Pharmacosmos A/S is involved in research for extensive-stage small cell lung cancer, with attention to treatment settings that combine anticancer therapy with supportive measures during chemotherapy.

Small cell lung cancer
Supportive oncology
Chemotherapy-associated care

The oncology portfolio shows interest in maintaining treatment tolerance and clinical outcomes in aggressive lung cancer care.

Iron Metabolism and Pharmacology

Additional research activity includes studies in healthy volunteers examining how candidate medicines are processed in the body, indicating interest in drug absorption, distribution, and elimination for iron-related compounds.

Pharmacokinetics
Oral and injectable formulations
Iron-based therapeutics

This work aligns with the sponsor’s broader focus on medicines for iron homeostasis and disorders linked to abnormal iron handling.

Trial Name	Country	Status
A Pharmacokinetic Comparison of Two Oral Formulations of Petadeferitrin in Healthy Volunteers	The Netherlands	Not Yet Recruiting
A Randomized, Double-Blind, Placebo-Controlled Study of Trilaciclib vs Placebo in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan Chemotherapy	Austria Belgium Bulgaria Germany Greece Hungary Poland Spain	Not Recruiting
Comparative Phase III Trial of Ferric Derisomaltose Versus No Intravenous Iron in Iron-Deficient Patients with Symptomatic Chronic Heart Failure	Bulgaria Croatia Czechia Denmark Hungary Latvia Lithuania Norway Poland Portugal Romania Slovakia	Recruiting
Dose-Escalation and Dose-Finding Study of (S)-4,5-Dihydro-2-[2-Hydroxy-4-(3,6-Dioxaheptyloxy)phenyl]-4-Methyl-4-Thiazolecarboxylic Acid in Transfusion-Dependent α- or β-Thalassemia	Denmark Greece Italy Poland	Recruiting